Patents by Inventor Paul R. Ervin, Jr.

Paul R. Ervin, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND COMPOSITIONS FOR DIAGNOSING BREAST CANCER
    Publication number: 20110039279
    Abstract: Mammastatin has an approximate molecular weight of 44 kDa in its inactive, non-phosphorylated form. Normal mammary cells express functional phosphorylated forms having approximate molecular weights of 53 kDa and 49 kDa. Metastatic mammary cells either do not express Mammastatin at all, or do not express the 53 kDa or 49 kDa, phosphorylated forms. Mammary cancer cells are inhibited in their growth by the administration of phosphorylated Mammastatin.
    Type: Application
    Filed: September 22, 2010
    Publication date: February 17, 2011
    Inventor: Paul R. Ervin, JR.
  • NUCLEOTIDE AND PROTEIN SEQUENCE OF MAMMASTATIN AND METHODS OF USE
    Publication number: 20110003318
    Abstract: A nucleic acid sequence encoding Mammastatin, a specific mammary cell growth inhibitor. Mammastatin is encoded by a single nucleic acid sequence and has an approximate molecular weight of 44 kDa in its inactive, non-phosphorylated form. Normal mammary cells express functional phosphorylated forms having approximate molecular weights of 53 kDa and 49 kDa. Metastatic mammary cells either do not express Mammastatin at all, or do not express the 53 kDa or 49 kDa, phosphorylated forms. Mammary cancer cells are inhibited in their growth by the administration of phosphorylated mammastatin.
    Type: Application
    Filed: July 29, 2010
    Publication date: January 6, 2011
    Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventor: Paul R. Ervin, JR.
  • Methods And Compositions For Diagnosing Breast Cancer
    Publication number: 20090011434
    Abstract: Mammastatin has an approximate molecular weight of 44 kDa in its inactive, non-phosphorylated form. Normal mammary cells express functional phosphorylated forms having approximate molecular weights of 53 kDa and 49 kDa. Metastatic mammary cells either do not express Mammastatin at all, or do not express the 53 kDa or 49 kDa, phosphorylated forms. Mammary cancer cells are inhibited in their growth by the administration of phosphorylated Mammastatin.
    Type: Application
    Filed: February 7, 2008
    Publication date: January 8, 2009
    Applicant: The Regents of the University of Michigan
    Inventor: Paul R. Ervin, JR.
  • Methods and compositions for diagnosing breast cancer
    Patent number: 7332287
    Abstract: Mammastatin has an approximate molecular weight of 44 kDa in its inactive, non-phosphorylated form. Normal mammary cells express functional phosphorylated forms having approximate molecular weights of 53 kDa and 49 kDa. Metastatic mammary cells either do not express Mammastatin at all, or do not express the 53 kDa or 49 kDa, phosphorylated forms. Mammary cancer cells are inhibited in their growth by the administration of phosphorylated Mammastatin.
    Type: Grant
    Filed: July 9, 2002
    Date of Patent: February 19, 2008
    Assignee: The Regents of the University of Michigan
    Inventor: Paul R. Ervin, Jr.
  • Methods for treating breast cancer using a mammary cell growth inhibitor
    Patent number: 7323173
    Abstract: Mammastatin has an approximate molecular weight of 44 kDa in its inactive, non-phosphorylated form. Normal mammary cells express functional phosphorylated forms having approximate molecular weights of 53 kDa and 49 kDa. Metastatic mammary cells either do not express Mammastatin at all, or do not express the 53 kDa or 49 kDa, phosphorylated forms. Mammary cancer cells are inhibited in their growth by the administration of phosphorylated Mammastatin.
    Type: Grant
    Filed: July 9, 2002
    Date of Patent: January 29, 2008
    Assignee: The Regents of the University of Michigan
    Inventor: Paul R. Ervin, Jr.
  • Nucleotide and protein sequence of mammastatin and methods of use
    Patent number: 7256277
    Abstract: A nucleic acid sequence encoding Mammastatin, a specific mammary cell growth inhibitor. Mammastatin is encoded by a single nucleic acid sequence and has an approximate molecular weight of 44 kDa in its inactive, non-phosphorylated form. Normal mammary cells express functional phosphorylated forms having approximate molecular weights of 53 kDa and 49 kDa. Metastatic mammary cells either do not express Mammastatin at all, or do not express the 53 kDa or 49 kDa, phosphorylated forms. Mammary cancer cells are inhibited in their growth by the administration of phosphorylated mammastatin.
    Type: Grant
    Filed: June 11, 2003
    Date of Patent: August 14, 2007
    Assignee: Regents of the University of Michigan
    Inventor: Paul R. Ervin, Jr.
  • Epithelial cell growth inhibitors
    Patent number: 6939714
    Abstract: Epithelial cell growth inhibitors differentially express in normal and cancerous epithelial cells. The ECGI proteins and nucleic acid sequence encoding them are useful in the diagnosis and treatment of epithelial cell cancers, for example prostate, ovarian, colon cancer, and the like.
    Type: Grant
    Filed: December 18, 2001
    Date of Patent: September 6, 2005
    Assignee: Biotherapies, Inc.
    Inventor: Paul R. Ervin, Jr.
  • Nucleotide and protein sequence of mammastatin and methods of use
    Patent number: 6599495
    Abstract: A nucleic acid sequence encoding Mammastatin, a specific mammary cell growth inhibitor. Mammastatin is encoded by a single nucleic acid sequence and has an approximate molecular weight of 44 kDa in its inactive, non-phosphorylated form. Normal mammary cells express functional phosphorylated forms having approximate molecular weights of 53 kDa and 49 kDa. Metastatic mammary cells either do not express Mammastatin at all, or do not express the 53 kDa or 49 kDa, phosphorylated forms. Mammary cancer cells are inhibited in their growth by the administration of phosphorylated mammastatin.
    Type: Grant
    Filed: August 22, 2000
    Date of Patent: July 29, 2003
    Assignee: Regents of the University of Michigan
    Inventor: Paul R. Ervin, Jr.
  • Nucleotide sequence encoding a mammary cell growth inhibitor
    Patent number: 6500937
    Abstract: A nucleic acid sequence encoding Mammastatin, a specific mammary cell growth inhibitor. Mammastatin is encoded by a single nucleic acid sequence and has an approximate molecular weight of 44 kDa in its inactive, non-phosphorylated form. Normal mammary cells express functional phosphorylated forms having approximate molecular weights of 53 kDa and 49 kDa. Metastatic mammary cells either do not express Mammastatin at all, or do not express the 53 kDa or 49 kDa, phosphorylated forms. Mammary cancer cells are inhibited in their growth by the administration of phosphorylated mammastatin.
    Type: Grant
    Filed: December 19, 1997
    Date of Patent: December 31, 2002
    Assignee: University of Michigan
    Inventor: Paul R. Ervin, Jr.
  • Nucleotide sequence of mammastatin and methods of use
    Patent number: 6492504
    Abstract: A nucleic acid sequence encoding Mammastatin, a specific mammary cell growth inhibitor. Mammastatin is encoded by a single nucleic acid sequence and has an approximate molecular weight of 44 kDa in its inactive, non-phosphorylated form. Normal mammary cells express functional phosphorylated forms having approximate molecular weights of 53 kDa and 49 kDa. Metastatic mammary cells either do not express Mammastatin at all, or do not express the 53 kDa or 49 kDa, phosphorylated forms. Mammary cancer cells are inhibited in their growth by the administration of phosphorylated Mammastatin.
    Type: Grant
    Filed: August 6, 1999
    Date of Patent: December 10, 2002
    Assignee: The University of Michigan
    Inventor: Paul R. Ervin, Jr.
  • Methods for treating breast cancer using Mammastatin
    Patent number: 6451765
    Abstract: A nucleic acid sequence encoding Mammastatin, a specific mammary cell growth inhibitor. Mammastatin is encoded by a single nucleic acid sequence and has an approximate molecular weight of 44 kDa in its inactive, non-phosphorylated form. Normal mammary cells express functional phosphorylated forms having approximate molecular weights of 53 kDa and 49 kDa. Metastatic mammary cells either do not express Mammastatin at all, or do not express the 53 kDa or 49 kDa, phosphorylated forms. Mammary cancer cells are inhibited in their growth by the administration of phosphorylated Mammastatin.
    Type: Grant
    Filed: April 2, 1999
    Date of Patent: September 17, 2002
    Assignee: University of Michigan
    Inventor: Paul R. Ervin, Jr.
  • NUCLEOTIDE AND PROTEIN SEQUENCE OF MAMMASTATIN AND METHODS OF USE
    Publication number: 20020072592
    Abstract: A nucleic acid sequence encoding Mammastatin, a specific mammary cell growth inhibitor. Mammastatin is encoded by a single nucleic acid sequence and has an approximate molecular weight of 44 kDa in its inactive, non-phosphorylated form. Normal mammary cells express functional phosphorylated forms having approximate molecular weights of 53 kDa and 49 kDa. Metastatic mammary cells either do not express Mammastatin at all, or do not express the 53 kDa or 49 kDa, phosphorylated forms. Mammary cancer cells are inhibited in their growth by the ?administration of phosphorylated Mammastatin.
    Type: Application
    Filed: August 6, 1999
    Publication date: June 13, 2002
    Inventor: PAUL R. ERVIN, JR.